Medical Access in Saudi Arabia

Currently classified as a strictly controlled substance under Saudi narcotics and psychotropic laws, with no authorized medical use outside of approved clinical research. The Kingdom’s Executive Regulations for Combating Narcotics and Psychotropic Substances maintain lists of prohibited psychotropic agents and restrict importation, possession, manufacture and use except for authorised research or SFDA approvals [1]SFDA Executive Regulations. Penalties for possession and related offences are severe under the Law on Combating Narcotic Drugs and Psychotropic Substances; treatment/rehabilitation pathways are available for persons who present for care, but there is no routine medical or reimbursed clinical access to psilocybin outside approved research. [2]UNODC — Saudi Narcotics Law translation.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Saudi law and SFDA regulations place MDMA/related substituted amphetamines on controlled/forbidden lists; possession, import or distribution is criminalized and may carry severe penalties except where SFDA/competent authorities expressly permit research. [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.

Esketamine nasal spray (Spravato) is registered with the Saudi Food and Drug Authority and listed with risk‑minimisation requirements indicating regulated clinical availability in the Kingdom; the SFDA entry for Spravato confirms it as an approved anti‑depressant product subject to provider/patient guidance and monitoring requirements [1]SFDA Spravato page.

Regulatory framework and access: SFDA registration means Spravato may be imported, distributed and administered in licensed healthcare settings in Saudi Arabia, but the product is expected to be subject to restricted distribution and administration under local risk‑management guidance (mirroring international REMS‑style controls) and to be delivered only in supervised clinical settings. The SFDA risk‑minimization listing explicitly references safety concerns (blood pressure increases, transient dissociation, risk of abuse) and provides healthcare provider/patient materials, consistent with constrained clinic‑based administration [1]SFDA Spravato page.

Reimbursement and payer considerations: there is no public, centrally published SFDA statement that Spravato is universally reimbursed by Saudi public health payers. In practice, coverage for newly registered specialty psychiatric drugs in Saudi Arabia is determined by hospital formulary committees, the procuring public or private health system (e.g., Ministry of Health hospitals, military health services, and large private hospital groups), and insurance contracts. Because Spravato requires supervised administration and monitoring, access is normally via tertiary hospitals or specialised psychiatric units that choose to adopt the product; reimbursement is therefore variable and typically evaluated on a case‑by‑case basis by institutional procurement and the patient’s insurer (if any). The SFDA registration supports legal availability but does not by itself guarantee public reimbursement. [1]SFDA Spravato page.

Ketamine is an established anaesthetic and analgesic in Saudi Arabian hospitals and is routinely used in operating theatres, emergency departments and intensive care units; contemporary Saudi clinical literature documents IV and intramuscular ketamine use for sedation, analgesia, and in perioperative and critical care settings [1]Saudi clinical ketamine study [2]Emergency department ketamine use in Saudi EDs.

Regulation and psychiatric/off‑label use: as with most countries, intravenous and intramuscular ketamine is a regulated medicine dispensed and administered only by licensed healthcare providers in hospitals or authorised clinics. Off‑label psychiatric uses (e.g., intravenous ketamine for treatment‑resistant depression) occur in clinical practice worldwide and have been described in Saudi clinical literature and case series; however, such off‑label psychiatric use must follow institutional clinical governance, hospital pharmacy formulary rules, and narcotics/psychotropic prescribing regulations enforced by national authorities. Institutional protocols and monitoring requirements are typical when ketamine is used for psychiatric indications.

Reimbursement and access: because ketamine is a long‑established anaesthetic agent, its acquisition and inpatient administration are normally part of standard hospital pharmacy supply and are generally covered in the context of hospital care (public and private). For outpatient or specialised psychiatric ketamine services (e.g., repeated IV infusions for depression), reimbursement is less standardized and depends on the treating hospital / insurer; many such services, if offered, would be provided as hospital‑based procedures and billed through existing hospital payment mechanisms rather than via a community pharmacy prescription. (Sources: Saudi clinical publications and hospital practice reports). [1]Saudi clinical ketamine study [2]ED ketamine report.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The Kingdom’s executive regulations and narcotics law restrict DMT and related tryptamines unless expressly permitted for authorised scientific research by SFDA and competent authorities [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Possession, importation or distribution is subject to criminal penalties unless part of SFDA‑approved research; given the Kingdom’s broad prohibitions on psychotropic tryptamines, routine clinical access is not permitted. [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no regulatory pathway in Saudi Arabia for routine clinical ibogaine therapy; importation, possession or use would require explicit SFDA research approvals and otherwise is penalized under narcotics laws. [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Plants and preparations containing controlled tryptamines (DMT) and other psychotropic constituents are covered by the Kingdom’s prohibited substances lists and their importation/possession/use is unlawful except when expressly authorised for research by SFDA. Travelers should note strict importation rules for controlled substances. [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline and synthetic phenethylamines are subject to the Kingdom’s psychotropic/narcotic controls and prohibited unless SFDA‑approved for research purposes. Possession or trafficking carries severe criminal penalties. [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Substituted phenethylamines (the 2C family) are covered by Saudi controlled‑substance provisions and are not available clinically except within SFDA‑approved scientific studies. Criminal penalties apply for unapproved possession, import or distribution. [1]SFDA Executive Regulations [2]UNODC — Saudi Narcotics Law translation.